{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:19:40Z","timestamp":1787840380392,"version":"build-2784847793"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Fampridine is the only drug approved by the US Food and Drug Administration (FDA) for people with multiple sclerosis (MS) to improve their movement and has exhibited a clinically significant improvement in gait function in a subset of MS patients with Expanded Disability Status Scale (ESDSS) from 4 to 7. Nevertheless, this drug has been reported to possess some adverse effects (AEs) like seizure because of its pharmacological features. The aim of this study was to evaluate the incidence rate of post-medication side effects (SEs) of fampridine in MS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective cohort study includes MS patients aged between 18 and 65 years, referred to the neurology clinic of Kashani Hospital from April 2022 to October 2022, all with administration of fampridine (10 mg tablet twice daily according to the product specifications). Safety in these patients was monitored through monthly SEs checklist questions during 6 months of screening. SPSS version 18 was used to analyze the data of this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>From 319 participants screened at baseline, 254 patients with MS, including 127 relapsing-remitting multiple sclerosis (RRMS), 101 secondary progressive multiple sclerosis (SPMS), and 26 primary progressive multiple sclerosis (PPMS), were included in the study. The most observed AEs in SPMS and RRMS patients were dry mouth (13.9% vs. 15%) and insomnia (12.9% vs. 11%), respectively. Urinary tract infection (UTI) (11.5%) and stomachache (11.5%) were the most common SEs in PPMS patients. The most severe complication of the patients was back pain, while digestive complications were less severe. Also, insomnia and UTI were the patients\u2019 most persistent SEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The drug seems to be safe and well tolerated, as the SEs were mild and transient and they were consistent with most of the previous studies focusing on this medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpvm.ijpvm_292_23","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T12:02:40Z","timestamp":1738324960000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the Safety of Fampridine in Patients with Different Stages of Multiple Sclerosis"],"prefix":"10.4103","volume":"16","author":[{"given":"Saeed","family":"Vaheb","sequence":"first","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahour","family":"Farzan","sequence":"additional","affiliation":[{"name":"Students Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran"},{"name":"Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Afshari-Safavi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Ebrahimi","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1]]},"reference":[{"key":"R1-20250825","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00415-022-11359-6","article-title":"The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools","volume":"270","author":"Filser","year":"2023","journal-title":"J Neurol"},{"key":"R2-20250825","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jocn.2021.02.018","article-title":"Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorders by multiparametric quantitative MRI using convolutional neural network","volume":"87","author":"Hagiwara","year":"2021","journal-title":"J Clin Neuroscience"},{"key":"R3-20250825","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7861\/clinmed.2020-0292","article-title":"Clinical presentation and diagnosis of multiple sclerosis","volume":"20","author":"Ford","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"R4-20250825","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1212\/WNL.0000000000009754","article-title":"What is the role of axonal ion channels in multiple sclerosis?","volume":"95","author":"Correale","year":"2020","journal-title":"Neurology"},{"key":"R5-20250825","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3390\/ijms23052454","article-title":"Hydrogen ion dynamics as the fundamental link between neurodegenerative diseases and cancer: Its application to the therapeutics of neurodegenerative diseases with special emphasis on multiple sclerosis","volume":"23","author":"Harguindey","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R6-20250825","first-page":"100039","article-title":"Regional and global perspectives on the incidence of multiple sclerosis and neuromyelitis optica and its spectrum disorders from Asia with emphasis on China","volume":"3","author":"Viswanathan","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"R7-20250825","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00415-020-09696-5","article-title":"Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson's disease and matched controls during daily living","volume":"267","author":"Shah","year":"2020","journal-title":"J Neurol"},{"key":"R8-20250825","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418803248","article-title":"Prolonged-release fampridine in multiple sclerosis: Clinical data and real-world experience. Report of an expert meeting","volume":"11","author":"Albrecht","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"R9-20250825","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2174\/1381612827666210920151231","article-title":"Treatment options in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"28","author":"Rommer","year":"2022","journal-title":"Curr Pharm Des"},{"key":"R10-20250825","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann Neurol"},{"key":"R11-20250825","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s10072-023-06795-9","article-title":"Fampridine for gait imbalance in patients with multiple sclerosis (MS): A systematic review and meta-analysis","volume":"44","author":"Ghorbanpour","year":"2023","journal-title":"Neurol Sci"},{"key":"R12-20250825","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/nmt-2020-0024","article-title":"Efficacy and safety of fampridine for walking disability in multiple sclerosis","volume":"10","author":"Arp\u00edn","year":"2020","journal-title":"Neurodegener Dis Manag"},{"key":"R13-20250825","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.clinthera.2012.03.007","article-title":"The safety profile of dalfampridine extended release in multiple sclerosis clinical trials","volume":"34","author":"Cornblath","year":"2012","journal-title":"Clin Ther"},{"key":"R14-20250825","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s40265-017-0808-z","article-title":"Fampridine prolonged release: A review in multiple sclerosis patients with walking disability","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"R15-20250825","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"R16-20250825","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: Results of an International survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"R17-20250825","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1352458512463769","article-title":"Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis","volume":"19","author":"Krishnan","year":"2013","journal-title":"Mult Scler J"},{"key":"R18-20250825","doi-asserted-by":"crossref","first-page":"102188","DOI":"10.1016\/j.msard.2020.102188","article-title":"The effect of fampridine on the risk of seizure in patients with multiple sclerosis","volume":"43","author":"Etemadifar","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R19-20250825","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00415-020-09696-5","article-title":"Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson's disease and matched controls during daily living","volume":"267","author":"Shah","year":"2020","journal-title":"J Neurol"},{"key":"R20-20250825","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ana.21381","article-title":"Imaging correlates of decreased axonal Na+\/K+ATPase in chronic multiple sclerosis lesions","volume":"63","author":"Young","year":"2008","journal-title":"Ann Neurol"},{"key":"R21-20250825","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.3390\/ijms22147277","article-title":"Ion channels as new attractive targets to improve re-myelination processes in the brain","volume":"22","author":"Cherchi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R22-20250825","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1352458512463769","article-title":"Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis","volume":"19","author":"Krishnan","year":"2012","journal-title":"Mult Scler J"},{"key":"R23-20250825","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/164_2019_333","article-title":"Exploiting the diversity of ion channels: Modulation of ion channels for therapeutic indications","volume":"260","author":"Liu","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"R24-20250825","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.0000000000003656","article-title":"Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis","volume":"88","author":"Filli","year":"2017","journal-title":"Neurology"},{"key":"R25-20250825","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s12325-020-01606-5","article-title":"A Prospective, observational, cohort study to assess the efficacy and safety of prolonged-release fampridine in cognition, fatigue, depression, and quality of life in multiple sclerosis patients: The FAMILY study","volume":"38","author":"Mitsikostas","year":"2021","journal-title":"Adv Ther"},{"key":"R26-20250825","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s00415-018-8796-9","article-title":"Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years","volume":"265","author":"Broicher","year":"2018","journal-title":"J Neurol"},{"key":"R27-20250825","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1007\/s10072-021-05548-w","article-title":"Fampridine improves acute optic neuritis contributing to a long-lasting recovery of nerve function","volume":"42","author":"Boffa","year":"2021","journal-title":"Neurol Sci"},{"key":"R28-20250825","doi-asserted-by":"crossref","first-page":"36453","DOI":"10.1074\/jbc.M109.075523","article-title":"Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit","volume":"284","author":"Wu","year":"2009","journal-title":"J Biol Chem"},{"key":"R29-20250825","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.44.6.1054","article-title":"The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial","volume":"44","author":"Bever","year":"1994","journal-title":"Neurology"},{"key":"R30-20250825","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.48.4.817","article-title":"Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis","volume":"48","author":"Schwid","year":"1997","journal-title":"Neurology"},{"key":"R31-20250825","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","article-title":"Dose comparison trial of sustained-release fampridine in multiple sclerosis","volume":"71","author":"Goodman","year":"2008","journal-title":"Neurology"},{"key":"R32-20250825","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1352458506069538","article-title":"Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study","volume":"13","author":"Goodman","year":"2007","journal-title":"Mult Scler"},{"key":"R33-20250825","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"R34-20250825","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1177\/1352458514563591","article-title":"Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials","volume":"21","author":"Goodman","year":"2015","journal-title":"Mult Scler"},{"key":"R35-20250825","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/DHPS.S97113","article-title":"Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States","volume":"7","author":"Jara","year":"2015","journal-title":"Drug Healthc Patient Saf"},{"key":"R36-20250825","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1352458515581436","article-title":"Prolonged-release fampridine and walking and balance in MS: Randomised controlled MOBILE trial","volume":"22","author":"Hupperts","year":"2016","journal-title":"Mult Scler"},{"key":"R37-20250825","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40263-018-0586-5","article-title":"Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: Results from the randomized, double-blind, phase III ENHANCE trial of prolonged-release fampridine","volume":"33","author":"Hobart","year":"2019","journal-title":"CNS Drugs"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_292_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:21:48Z","timestamp":1787836908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_292_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_292_23","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2023-10-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}